New Report Shares Details about the Global Ophthalmic Drugs Contract Manufacturing Market by 2030

Basic information
Date of placement
24
0
0
  • <p>New Report Shares Details about the Global Ophthalmic Drugs
Contract Manufacturing Market by 2030</p> photo

Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Get Detailed Analysis: Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, an Key Market Insights · Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs · The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products · Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials · In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities · Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge · In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors · Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies · The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply · We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8% · In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers · Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain Type of product · Ophthalmic API · Ophthalmic drug FDF Type of FDF manufactured · Solid · Semi-solid · Liquid / suspension Type of primary packaging · Ampoule / vial · Glass / plastic bottle · Ointment tube · Blister packing · Other forms Scale of manufacturing · Clinical · Commercial Company size · Small · Mid-sized · Large · Very large Target disease indication · Age-related macular degeneration · Dry eye · Glaucoma · Other disease segments Key geographical regions · North America (US, Canada and Mexico) · Europe (UK, Germany, France, Spain, Italy and rest of Europe) · Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) · Rest of the world Request for Customization: Request Customization - Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, an The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain: · Akorn · Akums · Bal Pharma · Catalent · Cayman Chemical · Entod Pharmaceuticals · Farmigea · Glenmark Pharmaceuticals · Indiana Ophthalmics · Lomapharm · Medichem · Pillar5 Pharma · Recipharm · Salvat · Sterling Pharmaceutical Services · Sunways India Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Company Competitiveness Analysis 6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles 7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles 8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles 9. Clinical Trial Analysis 10. Capacity Analysis 11. Demand Analysis 12. Market Forecast 13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies 14. SWOT Analysis 15. Survey Analysis 16. Executive Insights 17. Future Growth Opportunities 18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers 19. Appendix 2: Tabulated Data 20. Appendix 3: List of Companies and Organizations Get Latest PDF Sample of this Report: Request Sample - Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, an

(0)
0.0
Dislike 0
ОТН 0
Like 0
 
Someone is typing...
I agree and close
x We use cookies to measure visitor statistics, personalize ads and customize the functionality of the site. You agree to this by using the website